The Valley Desk

NCT06479135 · Interventional trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Overall registry status Recruiting

Phase 3

Conditions MF, Myelofibrosis, Post-ET Myelofibrosis, Post-PV MF, Primary Myelofibrosis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov